Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787065 | 1.00 | GAA (0.32) | GAAMAPTIDO1L3MBTL1CHRNB2 | |
| SCHEMBL1937430 | 0.83 | TNKS2 (0.32) | CHRNB2CHRNA4SIGMAR1CHRNA7CYP2A6 | |
| SCHEMBL30365757 | 0.82 | — | — | |
| SCHEMBL7834684 | 0.78 | — | — | |
| SCHEMBL19540043 | 0.77 | CHRNB2 (0.32) | MAPTCHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL35212107 | 0.74 | — | — | |
| SCHEMBL31095199 | 0.73 | GAA (0.44) | GAAMAPTIDO1L3MBTL1CHRNB2 | |
| SCHEMBL34295 | 0.71 | GAA (0.48) | GAAMAPT | |
| SCHEMBL29415525 | 0.71 | GAA (0.48) | GAAMAPT | |
| SCHEMBL9732217 | 0.71 | GAA (0.32) | GAAMAPTIDO1L3MBTL1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | claimed |
| CN-110433162-A | It can be used as the dihydronaphthridine and related compound of the kinase inhibitor for treating proliferative disease | DECIPHERA PHARMACEUTICALS LLC | 2019-11-12 | — | — | CN | claimed |
| CN-110403938-A | It can be used as the dihydronaphthridine and related compound of the kinase inhibitor for treating proliferative disease | DECIPHERA PHARMACEUTICALS LLC | 2019-11-05 | — | — | CN | claimed |
| CN-103814027-A | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and their use as C5A receptor modulators | NOVARTIS AG | 2014-05-21 | — | — | CN | claimed |
| CN-101925383-A | Carboxamide compounds and their use as chemokine receptor agonists | EPIX DELAWARE INC | 2010-12-22 | — | — | CN | claimed |
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2024220641-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 USEFUL FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024097805-A1 | MIXED LINEAGE KINASE DOMAIN LIKE PSEUDOKINASE (MLKL) ACTIVATORS | TRUSTEES OF TUFTS COLLEGE (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| CN-111094286-B | 1, 2-dihydro-1, 6-naphthyridine derivatives, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2007134077-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-7291449-B2 | Silver halide photographic material and methine dye | FUJIFILM CORPORATION (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291449-B2 | Silver halide photographic material and methine dye | FUJIFILM CORPORATION (JP) | 2007-11-06 | — | — | US | disclosed |
| CN-101039920-A | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | AVENTIS PHARMA INC (US) | 2007-09-19 | — | — | CN | disclosed |
| EP-1307453-A2 | DIHYDRONAPHTHYRIDINE- AND DIHYDROPYRROLOPYRIDINE-DERIVATED COMPOUNDS AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020099070-A1 | Dihydronaphthyridine potassium channel openers | ABBOTT LABORATORIES | 2002-07-25 | — | — | US | disclosed |
| WO-2002010164-A2 | DIHYDRONAPHTHYRIDINE- AND DIHYDROPYRROLOPYRIDINE-DERIVATED COMPOUNDS AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-02-07 | — | — | WO | disclosed |
| CN-1297440-A | Piperidinyl and N-amidinopiperidinyl derivatives | AVENTIS PHARMA INC (US) | 2001-05-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | GAA 3120/4885MAPT 4593/4885IDO1 581/4885 |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | GAA 932/4885MAPT 2089/4885IDO1 4394/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | GAA 932/4885MAPT 2089/4885IDO1 4394/4885 |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | GAA 932/4885MAPT 2089/4885IDO1 4394/4885 |
| US-20020099070-A1 | Dihydronaphthyridine potassium channel openers | KCNH1, KCNN1, KCNJ2 | GAA 1909/4885MAPT 2301/4885IDO1 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.